Over the course of the past decades, our IOL technology has continued to improve, particularly with the ability to address presbyopia.
Today we are fortunate to have three FDA-approved diffractive IOL designs that provide a full range of uncorrected vision for our cataract surgery patients. With these new options, we anticipate a greater uptake and patient acceptance to the benefits of these IOL designs.
Older design refractive multifocal IOLs were phased out about 20 years ago as new diffractive technology models came to market. These new designs provided two distinct (Read more...)